BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, April 21, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 2010

View Archived Issues

New Pim kinase inhibitor ARRY-770 reduces airway hyperresponsiveness in mice

Read More

Adalimumab improves quality of life in Crohn's disease patients

Read More

Evotec Neurosciences claims bradykinin B1 receptor antagonists

Read More

CETP gene polymorphism linked to reduced risk for dementia

Read More

Topical WBI-1001 improves atopic dermatitis in double-blind trial

Read More

Roche discovers new GlyT-1 inhibitors

Read More

Merck KGaA discloses novel tyrosine kinase inhibitors

Read More

Bayer Schering claims new adenosine A1 receptor antagonists

Read More

Sanofi-aventis patents new cannabinoid CB1 receptor antagonists

Read More

NIAID awards PDS phase II grant for HPV cancer vaccine

Read More

Ark withdraws Cerepro MAA after EMA's request for further trial in malignant glioma

Read More

Vernalis terminates agreement with PCH and regains rights to frovatriptan

Read More

Biotie and Pfizer to end discovery phase of development of PDE10 inhibitors for schizophrenia

Read More

Stanford University requests data from Favrille's cancer vaccine trials

Read More

Ischemix begins phase IIa CMX-2043 trial in ischemia reperfusion injury

Read More

Ista receives action date for FDA review of XiDay sNDA

Read More

Chimerix begins phase II CMX-001 study in CMV-seropositive stem cell transplant recipients

Read More

Bristol-Myers and AstraZeneca begin phase IV Onglyza trial

Read More

Enrollment begins in phase IIb trial of NTx-265 in acute ischemic stroke

Read More

mtm laboratories launches cervical cancer test CINtec Plus in Europe

Read More

Omthera to advance Epanova for hypertriglyceridemia

Read More

Celltrion develops broad-spectrum human monoclonal antibodies against influenza

Read More

Omeros licenses Asubio's PDE7 inhibitors for movement disorders

Read More

Harvard and Dana-Farber grant Acetylon exclusive license to HDAC inhibitor discovery platform

Read More

Abbott and GSK to develop molecular diagnostic test for skin cancer treatment

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 20, 2026.
  • Man holding raised arm with illustrated overlay of nerves

    Biohaven reports details on discovery of BHV-2100

    BioWorld Science
    Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • New GABA(B) receptor PAMs revealed in Addex Pharma patents

    BioWorld Science
    Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
  • Novel caspase-2 inhibitor shows in vivo neuroprotective effects

    BioWorld Science
    Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing